Clinical Trial Update: A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease [Phase 2]

View source ↗

Summary

Phase 2 long-term study assessing macitentan for heart failure with preserved ejection fraction and pulmonary vascular disease. The trial was terminated and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Pulmonary Vascular Disease

Drugs mentioned

• Macitentan (macitentan)

Snippet

Sponsor: Actelion | Conditions: Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease | Phase 2 | Status: TERMINATED | Results posted: 2022-11-04